Aurora Biosciences and Integrative Proteomics Announce Strategic Alliance And License Agreement for Drug Discovery Capabilities

Apr 19, 2001, 01:00 ET from Aurora Biosciences Corporation from ,Integrative Proteomics, Inc.

    SAN DIEGO and TORONTO, April 19 /PRNewswire/ -- Aurora Biosciences
 Corporation (Nasdaq:   ABSC) and Integrative Proteomics(TM), Inc. ("IPI") today
 announced that they have entered into a strategic alliance and license
 agreement for Aurora's high-throughput drug discovery capabilities based on
 Aurora's Big Biology(TM) and chemistry platforms to generate a set of
 approximately three and one-half million data points using IPI targets at
 Aurora's discovery facility over the next two years.
     Under the terms of the agreement, Aurora has agreed to deploy its high-
 throughput Big Biology platform to rapidly generate biochemical and cell-based
 assays to screen IPI targets for IPI's structure-guided discovery programs.
 IPI will license Aurora's leading discovery technologies for pharmaceutical
 applications and will make an upfront technology access fee, license fees and
 annual research support payments to Aurora.  Aurora will also capture
 downstream revenues from certain pharmaceutical products that may result from
 the use of Aurora's compounds and screens in the collaboration.  In addition,
 Aurora will make a strategic equity investment in IPI's next equity financing.
 Financial details were not disclosed.
     IPI will expand its integrated, multidisciplinary Pharmaceutical
 Proteomics(TM) Platform via its discovery alliance with Aurora.  Under the
 terms of the alliance announced today, IPI will gain access to Aurora's
 proprietary collection of over 500,000 compounds through Aurora's screening of
 IPI targets.  In addition, IPI will license a suite of Aurora's advanced,
 proprietary discovery technologies, including GFP functional genomic
 technologies and reporter systems for target-centric discovery for important
 classes of pharmaceutical targets, including kinases, phosphatases, proteases,
 nuclear receptors and GPCRs, as well as Aurora's Vivid(TM) fluorogenic
 substrates for ADME/Tox applications.  The alliance also includes a
 collaboration on new protein-protein interaction technologies based on
 Aurora's leading reporter systems.  IPI will collaborate with Aurora to
 determine structures of targets being pursued in Aurora's Big Biology
 initiative.
     "We are very impressed with Integrative Proteomics' ability to link the
 function of proteins with their high-throughput 3D structure determination
 process in a drug discovery context.  We are excited about the opportunity to
 work with IPI and to apply our Big Biology platform to IPI's targets," stated
 Stuart J.M. Collinson, Ph.D., Aurora's chairman, chief executive officer and
 president.  "The IPI alliance advances Aurora's continuing objective to expand
 its internal drug discovery capabilities through strategic collaborations with
 technology-rich biotechnology and pharmaceutical companies."
     "Aurora's Big Biology platform leads the industry in the capacity and
 efficiency it can bring to the discovery process and adds significant value to
 IPI's growing estate of discovery technologies for high-throughput
 interrogation of target function and structure," stated John D. Mendlein,
 Ph.D., Integrative Proteomics' chairman and chief executive officer.
 "Aurora's drug discovery strengths and compound collections will rapidly jump-
 start our internal discovery efforts using IPI targets.  We also welcome
 Aurora's future investment in IPI, and look forward to using the results of
 this alliance in our structure-guided discovery programs."
 
     Integrative Proteomics(TM) ("IPI") accelerates the discovery of new
 medicines using its Pharmaceutical Proteomics(TM) Platform.  Using leading
 structural proteomics technologies, IPI plans to build the world's first
 integrated, industrial platform for high-throughput pharmaceutical target
 function/structure interrogation using X-ray, NMR and mass spectrometry
 technologies from Bruker AXS, Bruker BioSpin and Bruker Daltonics,
 respectively.  IPI's ProteoWorks(TM) Platform for rapid, parallel production
 of recombinant proteins from bioinformatic databases uses proprietary protein
 expression and purification processes based on IPI's advances in molecular
 biology and mass spectroscopy that eliminate many of the bottlenecks
 associated with conventional protein production systems.  IPI's
 ProteoActive(TM) Platform monitors protein-protein interactions using a
 proprietary mass spectrometry system, which compiles functional information in
 a proprietary database to assess the function and therapeutic relevance of
 proteins in a cellular context.  IPI's ProteoVision(TM) Platform uses
 proprietary NMR and X-ray crystallography systems to accelerate the
 determination of protein structure to guide small molecule design and library
 selection, hit selection and lead optimization.  IPI has 45 employees,
 70 percent with advanced degrees.  IPI is located in Toronto, Canada and plans
 to open a U.S. site in the first half of 2001.  IPI's investors include the
 Canadian-based venture firm of CC Capital Partners, Eastern Technology Seed
 Investment Fund and Lombard Odier of Switzerland.
 
     Aurora Biosciences(R) is a drug discovery company that uses proprietary
 advances in biology, chemistry and automation to accelerate the discovery of
 new medicines.  Aurora's core technologies include a broad portfolio of
 proprietary fluorescence assay technologies and screening platforms designed
 to provide an integrated solution for drug discovery.  Aurora's fluorescence
 assay technologies include GeneBLAzer(TM), GenomeScreen(TM),
 PhosphoryLIGHT(TM) and Vivid(TM) technologies, as well as a broad collection
 of fluorescent proteins.  Aurora's screening platforms include an ultra-high
 throughput screening system, the UHTSS(R) Platform, Aurora's automated master
 compound store, the AMCS, and an ion channel technology screening platform,
 which includes Aurora's proprietary voltage sensor probes and a voltage ion
 probe reader, the VIPR(TM) subsystem.  Aurora also provides assay development
 and screening services as part of its drug discovery collaborations.  Aurora's
 Big Biology(TM) initiative is an internal drug discovery program focused on
 the identification of promising preclinical candidates within all major
 classes of gene targets.  Aurora's technologies and drug discovery
 capabilities have been commercially validated by over 20 major life sciences
 companies and research organizations, including American Home Products,
 Bristol-Myers Squibb, Ceres, Cystic Fibrosis Foundation, Eli Lilly, Families
 of SMA, GlaxoSmithKline, Genentech, Johnson & Johnson, Merck, NV Organon
 Laboratories, Pfizer, Pharmacia and Roche.  For additional information on
 Aurora's services and products, please contact Sales and Marketing via email
 at marcom@aurorabio.com.
 
     Statements in this press release that are not strictly historical are
 "forward-looking" statements which involve a high degree of technological and
 competitive risks and uncertainties that exist in Aurora's operations and
 business environment.  Such forward-looking statements include statements
 relating to Aurora's ability to perform services under its agreement with IPI
 and Aurora's potential future revenues under that agreement.  Such statements
 are only predictions and Aurora's actual events or results may differ
 materially from those projected in such forward-looking statements.  Factors
 that could cause or contribute to differences include Aurora's ability to
 develop and commercialize new technologies, as well as commercial acceptance
 of such technologies, Aurora's ability to rapidly identify promising drug
 candidates through its Big Biology initiative, Aurora's dependence on patents
 and proprietary rights, Aurora's ability to generate additional sales of
 products and services, Aurora's dependence on pharmaceutical and biotechnology
 collaborations and the development or availability of competing technologies,
 products or services.  These factors and others are more fully described in
 Aurora's Annual Report on Form 10-K for the fiscal year ended December 31,
 2000, as filed with the Securities and Exchange Commission.  For additional
 corporate information, visit the Aurora website at http://www.aurorabio.com.
 
     Aurora Biosciences(R), Big Biology(TM), GeneBLAzer(TM), GenomeScreen(TM),
 PhosphoryLIGHT(TM), UHTSS(R), VIPR(TM) and Vivid(TM) are trademarks of Aurora
 Biosciences Corporation.
 
     Pharmaceutical Proteomics(TM), ProteoWorks(TM), ProteoActive(TM), and
 ProteoVision(TM) are trademarks of Integrative Proteomics, Inc.
 
 

SOURCE Aurora Biosciences Corporation; Integrative Proteomics, Inc.
    SAN DIEGO and TORONTO, April 19 /PRNewswire/ -- Aurora Biosciences
 Corporation (Nasdaq:   ABSC) and Integrative Proteomics(TM), Inc. ("IPI") today
 announced that they have entered into a strategic alliance and license
 agreement for Aurora's high-throughput drug discovery capabilities based on
 Aurora's Big Biology(TM) and chemistry platforms to generate a set of
 approximately three and one-half million data points using IPI targets at
 Aurora's discovery facility over the next two years.
     Under the terms of the agreement, Aurora has agreed to deploy its high-
 throughput Big Biology platform to rapidly generate biochemical and cell-based
 assays to screen IPI targets for IPI's structure-guided discovery programs.
 IPI will license Aurora's leading discovery technologies for pharmaceutical
 applications and will make an upfront technology access fee, license fees and
 annual research support payments to Aurora.  Aurora will also capture
 downstream revenues from certain pharmaceutical products that may result from
 the use of Aurora's compounds and screens in the collaboration.  In addition,
 Aurora will make a strategic equity investment in IPI's next equity financing.
 Financial details were not disclosed.
     IPI will expand its integrated, multidisciplinary Pharmaceutical
 Proteomics(TM) Platform via its discovery alliance with Aurora.  Under the
 terms of the alliance announced today, IPI will gain access to Aurora's
 proprietary collection of over 500,000 compounds through Aurora's screening of
 IPI targets.  In addition, IPI will license a suite of Aurora's advanced,
 proprietary discovery technologies, including GFP functional genomic
 technologies and reporter systems for target-centric discovery for important
 classes of pharmaceutical targets, including kinases, phosphatases, proteases,
 nuclear receptors and GPCRs, as well as Aurora's Vivid(TM) fluorogenic
 substrates for ADME/Tox applications.  The alliance also includes a
 collaboration on new protein-protein interaction technologies based on
 Aurora's leading reporter systems.  IPI will collaborate with Aurora to
 determine structures of targets being pursued in Aurora's Big Biology
 initiative.
     "We are very impressed with Integrative Proteomics' ability to link the
 function of proteins with their high-throughput 3D structure determination
 process in a drug discovery context.  We are excited about the opportunity to
 work with IPI and to apply our Big Biology platform to IPI's targets," stated
 Stuart J.M. Collinson, Ph.D., Aurora's chairman, chief executive officer and
 president.  "The IPI alliance advances Aurora's continuing objective to expand
 its internal drug discovery capabilities through strategic collaborations with
 technology-rich biotechnology and pharmaceutical companies."
     "Aurora's Big Biology platform leads the industry in the capacity and
 efficiency it can bring to the discovery process and adds significant value to
 IPI's growing estate of discovery technologies for high-throughput
 interrogation of target function and structure," stated John D. Mendlein,
 Ph.D., Integrative Proteomics' chairman and chief executive officer.
 "Aurora's drug discovery strengths and compound collections will rapidly jump-
 start our internal discovery efforts using IPI targets.  We also welcome
 Aurora's future investment in IPI, and look forward to using the results of
 this alliance in our structure-guided discovery programs."
 
     Integrative Proteomics(TM) ("IPI") accelerates the discovery of new
 medicines using its Pharmaceutical Proteomics(TM) Platform.  Using leading
 structural proteomics technologies, IPI plans to build the world's first
 integrated, industrial platform for high-throughput pharmaceutical target
 function/structure interrogation using X-ray, NMR and mass spectrometry
 technologies from Bruker AXS, Bruker BioSpin and Bruker Daltonics,
 respectively.  IPI's ProteoWorks(TM) Platform for rapid, parallel production
 of recombinant proteins from bioinformatic databases uses proprietary protein
 expression and purification processes based on IPI's advances in molecular
 biology and mass spectroscopy that eliminate many of the bottlenecks
 associated with conventional protein production systems.  IPI's
 ProteoActive(TM) Platform monitors protein-protein interactions using a
 proprietary mass spectrometry system, which compiles functional information in
 a proprietary database to assess the function and therapeutic relevance of
 proteins in a cellular context.  IPI's ProteoVision(TM) Platform uses
 proprietary NMR and X-ray crystallography systems to accelerate the
 determination of protein structure to guide small molecule design and library
 selection, hit selection and lead optimization.  IPI has 45 employees,
 70 percent with advanced degrees.  IPI is located in Toronto, Canada and plans
 to open a U.S. site in the first half of 2001.  IPI's investors include the
 Canadian-based venture firm of CC Capital Partners, Eastern Technology Seed
 Investment Fund and Lombard Odier of Switzerland.
 
     Aurora Biosciences(R) is a drug discovery company that uses proprietary
 advances in biology, chemistry and automation to accelerate the discovery of
 new medicines.  Aurora's core technologies include a broad portfolio of
 proprietary fluorescence assay technologies and screening platforms designed
 to provide an integrated solution for drug discovery.  Aurora's fluorescence
 assay technologies include GeneBLAzer(TM), GenomeScreen(TM),
 PhosphoryLIGHT(TM) and Vivid(TM) technologies, as well as a broad collection
 of fluorescent proteins.  Aurora's screening platforms include an ultra-high
 throughput screening system, the UHTSS(R) Platform, Aurora's automated master
 compound store, the AMCS, and an ion channel technology screening platform,
 which includes Aurora's proprietary voltage sensor probes and a voltage ion
 probe reader, the VIPR(TM) subsystem.  Aurora also provides assay development
 and screening services as part of its drug discovery collaborations.  Aurora's
 Big Biology(TM) initiative is an internal drug discovery program focused on
 the identification of promising preclinical candidates within all major
 classes of gene targets.  Aurora's technologies and drug discovery
 capabilities have been commercially validated by over 20 major life sciences
 companies and research organizations, including American Home Products,
 Bristol-Myers Squibb, Ceres, Cystic Fibrosis Foundation, Eli Lilly, Families
 of SMA, GlaxoSmithKline, Genentech, Johnson & Johnson, Merck, NV Organon
 Laboratories, Pfizer, Pharmacia and Roche.  For additional information on
 Aurora's services and products, please contact Sales and Marketing via email
 at marcom@aurorabio.com.
 
     Statements in this press release that are not strictly historical are
 "forward-looking" statements which involve a high degree of technological and
 competitive risks and uncertainties that exist in Aurora's operations and
 business environment.  Such forward-looking statements include statements
 relating to Aurora's ability to perform services under its agreement with IPI
 and Aurora's potential future revenues under that agreement.  Such statements
 are only predictions and Aurora's actual events or results may differ
 materially from those projected in such forward-looking statements.  Factors
 that could cause or contribute to differences include Aurora's ability to
 develop and commercialize new technologies, as well as commercial acceptance
 of such technologies, Aurora's ability to rapidly identify promising drug
 candidates through its Big Biology initiative, Aurora's dependence on patents
 and proprietary rights, Aurora's ability to generate additional sales of
 products and services, Aurora's dependence on pharmaceutical and biotechnology
 collaborations and the development or availability of competing technologies,
 products or services.  These factors and others are more fully described in
 Aurora's Annual Report on Form 10-K for the fiscal year ended December 31,
 2000, as filed with the Securities and Exchange Commission.  For additional
 corporate information, visit the Aurora website at http://www.aurorabio.com.
 
     Aurora Biosciences(R), Big Biology(TM), GeneBLAzer(TM), GenomeScreen(TM),
 PhosphoryLIGHT(TM), UHTSS(R), VIPR(TM) and Vivid(TM) are trademarks of Aurora
 Biosciences Corporation.
 
     Pharmaceutical Proteomics(TM), ProteoWorks(TM), ProteoActive(TM), and
 ProteoVision(TM) are trademarks of Integrative Proteomics, Inc.
 
 SOURCE  Aurora Biosciences Corporation; Integrative Proteomics, Inc.